Inventiva Launches Share Repurchase Program to Boost Market Liquidity

An announcement from Inventiva ( (IVA) ) is now available.

On May 22, 2025, Inventiva announced the approval of a share repurchase program by its Ordinary General Meeting. The program, designed to animate the market under a liquidity agreement with Kepler Chevreux, allows the company to repurchase up to 10% of its capital. The initiative aims to enhance market liquidity and support stock option programs for employees and corporate officers. The program will run for 18 months, reflecting Inventiva’s strategic efforts to stabilize its market presence and potentially improve shareholder value.

The most recent analyst rating on (IVA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.

Spark’s Take on IVA Stock

According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.

Inventiva’s overall stock score reflects significant financial difficulties and a challenging valuation, balanced by strong technical indicators and a cautiously optimistic outlook from the earnings call. Despite clinical progress, financial instability and operational inefficiencies present notable risks.

To see Spark’s full report on IVA stock, click here.

More about Inventiva

Inventiva is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies aimed at treating patients with MASH and other diseases with significant unmet medical needs. The company is currently conducting a pivotal Phase 3 clinical trial for lanifibranor, a novel pan-PPAR agonist, targeting adult patients with MASH, a progressive chronic liver disease. Inventiva is publicly traded on Euronext Paris and the Nasdaq Global Market.

Average Trading Volume: 15,439

Technical Sentiment Signal: Buy

Current Market Cap: $449.1M

For an in-depth examination of IVA stock, go to TipRanks’ Stock Analysis page.